Saxenda for weight loss: what TikTok gets right and wrong

What did @polybiotics actually say?

The creator gave a broadly structured overview of Saxenda (liraglutide) for weight loss, covering its mechanism, eligibility criteria, side effects, and the need for lifestyle changes alongside the medication. They mentioned that it works by mimicking GLP-1, helps people feel fuller, improves glucose handling, and requires daily subcutaneous injection. They also flagged thyroid cancer concerns from rat studies and listed side effects including nausea, pancreatitis, and gallstones. One of their more specific claims: you can only continue if you lose "5% of your body weight in 12 weeks on the maximum dose." That level of specificity is worth checking closely.

On tone, the creator is reasonably cautious and avoids promising dramatic results. They name the drug correctly (mispronunciations aside), explain the mechanism without oversimplifying, and correctly flag contraindications for people with personal or family history of thyroid problems or multiple endocrine neoplasia type 2 (MEN2).

Does the science back this up?

Mostly yes, but with some important caveats on the details. The core mechanism is accurate. Liraglutide is a GLP-1 receptor agonist, and GLP-1 is indeed secreted by intestinal L-cells postprandially. The drug reduces appetite and improves insulin sensitivity. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) confirmed that liraglutide 3.0mg led to a mean 8.4% body weight reduction over 56 weeks versus 2.5% with placebo.

The thyroid cancer concern from rat studies is real and correctly contextualized. The FDA black box warning exists based on rodent carcinogenicity data showing C-cell tumors in rats and mice. The creator is right that this has not been demonstrated in humans at clinical doses, though the warning still stands. The contraindication for MEN2 and personal or family history of medullary thyroid carcinoma is accurate per the FDA label.

The pancreatitis risk is documented. Post-marketing reports and pharmacovigilance data have flagged acute pancreatitis with GLP-1 receptor agonists, including liraglutide, though causality is still debated in the literature (Monami et al., 2017, Diabetes, Obesity and Metabolism).

What did they get wrong (or right)?

The drug name is mispronounced throughout as "sex-ender" and the active ingredient is called "lireglutide" rather than liraglutide. These are phonetic errors, not clinical ones, but worth flagging for a health information video.

The 5% benchmark is where things get slightly off. The creator says you need to lose 5% in "12 weeks on the maximum dose." The actual clinical guidance, per the NICE TA664 (2020) and the Saxenda prescribing information, specifies a 5% weight loss benchmark at 12 weeks, but this is assessed after reaching the maintenance dose of 3.0mg, which itself takes about 5 weeks to titrate up to. The framing is close enough to be considered mostly accurate, but the titration nuance matters clinically.

The creator also says liraglutide "was originally for diabetes." This is accurate. Victoza (liraglutide 1.8mg) was approved for type 2 diabetes in 2010. Saxenda (liraglutide 3.0mg) was approved for obesity in 2014. Credit where it is due: that historical context is correct.

On the claim that lifestyle changes prevent weight regain after stopping, the evidence is more complicated. The SCALE Maintenance extension data (Wadden et al., 2013) and the post-discontinuation data from the SUSTAIN/SCALE programs both show significant weight regain after stopping GLP-1 agonists, regardless of lifestyle adherence. The creator's framing that "those changes need to be implemented so that when you stop the drug you don't gain all the weight back" overstates what lifestyle changes can realistically do after cessation.

What should you actually know?

Saxenda is a legitimate, regulated treatment for obesity with a meaningful evidence base. It is not a shortcut and it is not appropriate for people who just want to lose a few pounds. The eligibility criteria the creator outlines are broadly accurate: BMI over 30, or BMI over 27 with weight-related comorbidities including hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.

What the video does not mention: Saxenda has largely been overshadowed in clinical practice by semaglutide (Wegovy) and tirzepatide (Mounjaro/Zepbound), which show greater efficacy in head-to-head data. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieving up to 22.5% mean weight reduction at 72 weeks, substantially more than liraglutide's documented outcomes. If you are considering GLP-1 therapy for weight management, Saxenda is not necessarily the first option a clinician would reach for in 2024.

Also unmentioned: cost and access. Saxenda is expensive without insurance coverage, and NHS prescribing in the UK is subject to specific pathway criteria. Anyone considering this medication should have a conversation with a qualified prescriber, not just a TikTok video.